XML 26 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE RECOGNITION
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. For a description of the products and services provided within each of the Company’s four reportable segments see Note 6, Segment and Geographic Information.

Net sales disaggregated by product category were as follows:
Year Ended December 31,
(in millions)202420232022
Equipment & Instruments$553 $628 $678 
CAD/CAM509 541 541 
Connected Technology Solutions$1,062 $1,169 $1,219 
Essential Dental Solutions$1,454 $1,468 $1,427 
Orthodontics$299 $339 $297 
Implants & Prosthetics 674 701 709 
Orthodontic and Implant Solutions$973 $1,040 $1,006 
Wellspect Healthcare$304 $288 $270 
Total net sales$3,793 $3,965 $3,922 


Net sales disaggregated by geographic region were as follows:
Year Ended December 31,
(in millions)202420232022
United States$1,348 $1,437 $1,392 
Europe1,518 1,550 1,559 
Rest of World927 978 971 
Total net sales$3,793 $3,965 $3,922 

Contract Assets and Liabilities

The Company does not typically have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer orthodontic treatments where the performance obligation has not yet been satisfied, and deferred revenue associated with loyalty points earned but not yet redeemed by customers under the Company’s loyalty point program. The Company had deferred revenue of $95 million and $49 million presented in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2024. The Company recorded deferred revenue of $91 million and $57 million presented in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at December 31, 2023. The Company recognized $79 million of revenue for the year ended December 31, 2024 which was previously deferred as of December 31, 2023. The amount recognized in the year ended December 31, 2024 includes a $9 million reduction in revenue for a refund reserve related to the realignment of the Byte aligner business as described in Note 18, Restructuring and Other Costs. The Company recognized $68 million of revenue for the year ended December 31, 2023 which was previously deferred as of December 31, 2022. The Company expects to recognize most of the remaining deferred revenue in net sales within the next twelve months.
Allowance for Doubtful Accounts

Accounts and notes receivable-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $14 million and $17 million at December 31, 2024 and 2023, respectively. For the years ended December 31, 2024 and 2023, changes to the allowance for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were not significant. Changes to the allowance for doubtful accounts are presented in Selling, general, and administrative expenses in the Consolidated Statements of Operations.